Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Sienna Biopharmaceuticals Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 4,983,333 shares of common stock of…
LabCorp Acquires Chiltern
Davis Polk is advising J.P. Morgan Securities LLC as financial adviser to LabCorp in connection with its approximately $1.2…
Biotoscana Investments $377.7 Million Initial Public Offering
Davis Polk advised Biotoscana Investments S.A. and the selling shareholders in connection with an initial public offering of…
Davis Polk Advises Pernix Therapeutics Holdings, Inc. on Its Refinancing Transactions
Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with a series of refinancing transactions that are…
Kala Pharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with the $103.5 million initial public…
Davis Polk Advises Mitsubishi Tanabe Pharma on Its Acquisition of NeuroDerm
Davis Polk is advising Mitsubishi Tanabe Pharma Corporation on its approximately $1.1 billion acquisition of NeuroDerm Ltd…
Akcea Therapeutics Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 17,968,750 shares of common stock of…
Dova Pharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers in connection with the $86.3 million initial public offering of common…
Mersana Therapeutics, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $75…
Evolent Health, Inc. Common Stock Secondary Offering
Davis Polk advised the representative of the several underwriters in connection with a secondary offering of 4,500,000…